OSIR - Osiris Therapeutics Stock Price, News & Analysis

$5.85 0.03 (0.52 %)
(As of 11/24/2017 09:14 AM ET)
Previous Close$5.82
Today's Range$5.85 - $5.78
52-Week Range$2.67 - $7.15
Volume3,075 shs
Average Volume22,492 shs
Market Capitalization$201.98 million
P/E RatioN/A
Dividend YieldN/A
Beta0.81

About Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics logoOsiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:OSIR
  • Previous Symbol: NASDAQ:OSIR
  • CUSIP68827R10

    Debt

    Debt-to-Equity RatioN/A
    Current RatioN/A
    Quick RatioN/A

    Price-To-Earnings

    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual Sales$59.87 million
    Price / Sales3.37
    Cash Flow$0.02 per share
    Price / Cash289.30
    Book ValueN/A
    Price / BookN/A

    Dividend

    Annual DividendN/A
    Dividend YieldN/A

    Profitability

    Trailing EPSN/A
    Net IncomeN/A
    Net MarginsN/A
    Return on EquityN/A
    Return on AssetsN/A

    Miscellaneous

    EmployeesN/A
    Outstanding Shares34,530,000

    Frequently Asked Questions for Osiris Therapeutics (OTCMKTS:OSIR)

    What is Osiris Therapeutics' stock symbol?

    Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."

    Who are some of Osiris Therapeutics' key competitors?

    Who are Osiris Therapeutics' key executives?

    Osiris Therapeutics' management team includes the folowing people:

    • Peter Friedli, Chairman of the Board (Age 62)
    • Jason Keefer, Interim President, Chief Executive Officer, Vice President of Marketing (Age 45)
    • Linda Palczuk, President, Chief Executive Officer (Age 55)
    • Linda L. Chang, Chief Financial Officer (Age 51)
    • Frank D. Czworka Jr., Vice President, General Manager of Wound Care (Age 46)
    • Adrian P. Mollo, General Counsel (Age 41)
    • Alla N. Danilkovitch Ph.D., Chief Scientific Officer (Age 51)
    • Thomas M. Brandt Jr., Independent Director (Age 63)
    • Thomas J. Knapp, Independent Director (Age 63)
    • Jay M. Moyes, Independent Director (Age 63)

    How do I buy Osiris Therapeutics stock?

    Shares of Osiris Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Osiris Therapeutics' stock price today?

    One share of Osiris Therapeutics stock can currently be purchased for approximately $5.85.

    How big of a company is Osiris Therapeutics?

    Osiris Therapeutics has a market capitalization of $201.98 million and generates $59.87 million in revenue each year.

    How can I contact Osiris Therapeutics?

    Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]


    MarketBeat Community Rating for Osiris Therapeutics (OSIR)

    Community Ranking:  1.7 out of 5 (star)
    Outperform Votes:  65 (Vote Outperform)
    Underperform Votes:  126 (Vote Underperform)
    Total Votes:  191
    MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Osiris Therapeutics (OTCMKTS:OSIR)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
    Consensus Rating:N/A (Score: NaN)
    Analysts' Consensus Price Target: N/A

    Consensus Price Target History for Osiris Therapeutics (OTCMKTS:OSIR)

    Price Target History for Osiris Therapeutics (OTCMKTS:OSIR)

    Analysts' Ratings History for Osiris Therapeutics (OTCMKTS:OSIR)

    Show:
    DateFirmActionRatingPrice TargetDetails
    3/16/2016Brean CapitalReiterated RatingSell$4.00View Rating Details
    2/2/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
    (Data available from 11/24/2015 forward)

    Earnings

    Earnings History and Estimates Chart for Osiris Therapeutics (OTCMKTS:OSIR)

    Earnings by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

    Earnings History by Quarter for Osiris Therapeutics (OTCMKTS OSIR)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details
    8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details
    5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details
    3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details
    11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details
    8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details
    5/12/2014($0.08)($0.02)$9.00 million$10.05 millionViewN/AView Earnings Details
    3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details
    11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details
    8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details
    5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details
    11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)

    Estimates

    Earnings Estimates for Osiris Therapeutics (OTCMKTS:OSIR)

    No earnings estimates for this company have been tracked by MarketBeat.com

    Dividends

    Dividend History by Quarter for Osiris Therapeutics (OTCMKTS OSIR)

    AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
    9/17/2015special$0.209/14/20159/16/20159/30/2015
    9/17/2015special$0.2010/14/201510/16/201510/30/2015
    (Data available from 1/1/2013 forward)

    Insider Trades

    Insider Trading and Institutional Ownership History for Osiris Therapeutics (OTCMKTS OSIR)

    Insider Ownership Percentage: 44.60%
    Institutional Ownership Percentage: 0.27%
    Insider Trades by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)
    Insider Trades by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

    Insider Trades by Quarter for Osiris Therapeutics (OTCMKTS OSIR)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  
    5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.21View SEC Filing  
    3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  
    11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.28View SEC Filing  
    11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  
    8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  
    (Data available from 1/1/2013 forward)

    Headlines

    Latest Headlines for Osiris Therapeutics (OTCMKTS OSIR)

    Source:
    DateHeadline
    Financial Survey: Senesco Technologies (SVON) versus Osiris Therapeutics (OSIR)Financial Survey: Senesco Technologies (SVON) versus Osiris Therapeutics (OSIR)
    www.americanbankingnews.com - November 21 at 7:33 PM

    Social Media

    Financials

    Chart

    Osiris Therapeutics (OTCMKTS OSIR) Chart for Friday, November, 24, 2017
    Loading chart…

    This page was last updated on 11/24/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.